A 10-patient investigator-initiated trial is a modest starting point, but the strategic architecture behind it is anything but modest. Tempest Therapeutics is deploying TPST-4003 not as a conventional ex vivo cell therapy requiring patient-specific manufacturing, but as an in vivo CAR-T candidate that uses CD7-targeted mRNA/LNP delivery to recruit endogenous CD4+ and CD8+ T-cells directly inside the patient. That distinction carries real commercial weight: if the approach holds up clinically, it sidesteps the manufacturing bottleneck that has kept approved CAR-T products expensive and logistically demanding. Pairing that delivery platform with a dual-target CD19/BCMA CAR construct designed for broad B-cell lineage depletion then points the program squarely at autoimmune indications, starting with myasthenia gravis and multiple sclerosis.
The collaboration with Hebei Senlang Biotechnology is structured to extract maximum efficiency from a small, focused dataset. Senlang brings operational depth: the company is already running a pivotal CD7 CAR-T trial in relapsed or refractory T-cell lymphoblastic lymphoma and leukemia, and Phase I data on CD7-targeted CAR-T in peripheral T-cell lymphoma have demonstrated a workable safety profile in this target class. Senlang also holds an exclusive option to negotiate a China license for TPST-4003, which means Tempest is effectively outsourcing its China regulatory and manufacturing risk while retaining global rights. First patient dosing is targeted for Q4 2026, with initial safety and pharmacodynamic readouts expected as early as the first half of 2027.
The pharmacodynamic endpoints tell you what Tempest actually needs to prove at this stage. The trial will track generation and expansion of peripheral blood CD4+ and CD8+ CAR-T cells alongside CD56+ CAR-NK cells, CAR transgene copy number, and the depth and kinetics of CD19+ B-cell depletion. Where clinically appropriate, investigators may also look for CAR-positive immune cells in cerebrospinal fluid, which matters enormously for MS and MG given their CNS and neuromuscular pathophysiology. Multiple sclerosis already has an active approved-drug landscape, so Tempest’s differentiation argument rests entirely on depth of immune reset rather than filling a vacant therapeutic category.
The single number to watch in the first-half 2027 readout is CAR transgene copy number per peripheral blood cell. That metric will determine whether the mRNA/LNP platform is generating meaningful, durable CAR expression in vivo, and without it, neither the B-cell depletion data nor the disease-specific clinical signals will be interpretable. Everything downstream, including Senlang’s decision on whether to exercise its China license option, hinges on that one pharmacological proof point.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
